CannabisNewsBreaks

ThursdayNov 11, 2021 1:32 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Enters into Cannabinoid Science

Flora Growth Corp. (NASDAQ: FLGC) recently announced the next stage of its development with the creation of Flora Pharma and the execution of an agreement to begin scientific clinical trials globally. Flora Pharma’s formation follows the acknowledgment and commitment by the management team and board of directors to move ahead with applied research initiatives in medical cannabis in order to become a leader in the discovery, development, manufacturing and commercialization of novel, phytocannabinoid-based prescription medicines and nutraceutical products to address a broad range of diseases. The company also signed an agreement to begin scientific clinical trials on the use of…

Continue Reading

WednesdayNov 10, 2021 11:17 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs for 2022. According to the update, the studies mentioned in the announcement represent only a fraction of Lexaria's 2022 work programs. “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for…

Continue Reading

MondayNov 08, 2021 2:49 pm

CannabisNewsBreaks – RYAH Group Inc. (CSE: RYAH) Receives Additional Order as Its Ecosystem Continues to Power Trials, Pilots and Studies in Plant-Based Medicine

RYAH Group (CSE: RYAH) today announced its receipt of an additional order for future shipments of hundreds of its proprietary RYAH Smart Dry Herb Inhalers and accessories to its United Kingdom-based industry partner, an international clinic undertaking one of the world’s largest and most comprehensive clinical trials in plant-based medicine. The order follows the recently announced initial shipment, and the devices will be used by a growing number of participants of the major U.K.-based clinical trial. Over the next five years, the trial is planned to engage tens of thousands of United Kingdom patients and aims to focus on studying the…

Continue Reading

MondayNov 08, 2021 1:09 pm

CannabisNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Announces Sell-Out of First Shipment of Keef Brands

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, sold out of its initial shipment of Keef Brands’ award-winning beverage line. The shipment was sent to the British Columbia Liquor Distribution Branch (“BCLDB”), the sole wholesale distributor of nonmedical cannabis in British Columbia. The product line is the number-one selling cannabis-infused beverage brand in the United States. The BCLDB shipment included two of the brands most popular options: Bubba Kush Root Beer and Orange Kush Classic Soda. The company noted that additional production runs are already underway to meet the strong customer…

Continue Reading

ThursdayNov 04, 2021 10:29 am

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Announces Entry into Phase 2 of Florida Expansion

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, has officially entered phase 2 of its Florida expansion plan. According to the update, the plan is ahead of schedule with this week’s delivery of 30 modular grow pods to Red White & Bloom Florida LLC (“RWBFL”), a Red White & Bloom Brands subsidiary, at its Apopka, Florida, cultivation location. Phase 2 started with the commissioning and OMMU approval of five pods that have been loaded and are growing plants. RWBFL is fast tracking the remaining 25 pods and expects to have…

Continue Reading

WednesdayNov 03, 2021 12:53 pm

CannabisNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Announces Strategic Engagement of MZ Group

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) today announced its engagement of international investor relations specialists MZ Group to lead a comprehensive strategic investor relations and financial communications program across all key markets. The partnership with MZ represents an investment in BevCanna’s go-forward growth strategy as the company rapidly accelerates its evolution into a diversified health and wellness company. “Cannabis is an emerging leader within the overall $4.5 trillion wellness market, with the product market projected to reach $90.4 billion by 2026, according to MarketsandMarkets,” said Ted Haberfield, chairman and president of MZ Group North America. “BevCanna leverages proprietary…

Continue Reading

WednesdayNov 03, 2021 11:43 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition, the company provided updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD for potentially treating hypertension and heart disease. “HYPER-H21-4 is the most ambitious study Lexaria has ever undertaken and is enabled from the successful outcomes from our other 2021 human hypertension studies,” said Lexaria CEO Chris Bunka in the news release. “Outcomes from this study could support Lexaria's goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as…

Continue Reading

WednesdayNov 03, 2021 11:16 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids, today announced its filing of an international patent application demonstrating neuroprotection and enhanced neuronal function using a rare cannabinoid for the potential treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s and others. The Patent Cooperation Treaty (“PCT”) application, entitled “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids,” specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection in a population of affected neurons. Further, the PCT application demonstrates the subject cannabinoid compound can also be used…

Continue Reading

MondayNov 01, 2021 12:52 pm

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) on Target to Become House of Brands, Great Channel Partner

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) recently welcomed former U.S. Congressman and now public policy consultant Ryan Costello to its board of directors. Costello is expected to deepen RWB’s U.S.-based representation, which is key as federal policy on cannabis shifts. The company also announced that it has built a new production facility to good manufacturing practice (“GMP”) specifications in Florida as part of an effort to capitalize on the growing cannabis derivative market there. The Florida facility is built to accommodate the demand for edibles. “Red White & Bloom has built a branded capsule and rosin line…

Continue Reading

FridayOct 29, 2021 1:10 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses

Lexaria Bioscience Corp. (NASDAQ: LEXX) was recently part of coverage by Zacks Small-Cap Research analysts based on its market potential. Zacks, which focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators, valued the company at $15 per share. The valuation was based on the company’s portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption and the multiple potential uses of the technology. The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods through existing manufacturer relationships.…

Continue Reading